HCW Biologics Inc., a preclinical stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases. The company's lead products include HCW9218, which is an injectable immunotherapeutic for patients with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as pulmonary fibrosis; and HCW9302 for auto-immune diseases, such as alopecia areata and metabolic diseases. It also develops HCW9201, a cell-based therapy that is in Phase II clinical trials for the treatment of patients with relapsed/refractory acute myeloid leukemia; and HCW9206 for the treatment of acute myeloid leukemia. The company was incorporated in 2018 and is headquartered in Miramar, Florida.

CEO

ISIN

US40423R2040

Listings

0 Comments

Share your thoughts

FAQ

What is HCW Biologics stock price today?▼

The current price of HCWB.BOATS is $0.25 USD — it has decreased by -30.83% in the past 24 hours. Watch HCW Biologics stock price performance more closely on the chart.

What is HCW Biologics stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange HCW Biologics stocks are traded under the ticker HCWB.BOATS.

What is HCW Biologics market cap?▼

Today HCW Biologics has the market capitalization of 663,070.8

When is the next HCW Biologics earnings date?▼

HCW Biologics is going to release the next earnings report on May 07, 2026.

What were HCW Biologics earnings last quarter?▼

HCWB.BOATS earnings for the last quarter are -4.13 USD per share, whereas the estimation was 1.58 USD resulting in a -361.39% surprise. The estimated earnings for the next quarter are N/A USD per share.

What is HCW Biologics revenue for the last year?▼

HCW Biologics revenue for the last year amounts to 5.13M USD.

What is HCW Biologics net income for the last year?▼

HCWB.BOATS net income for the last year is -60.05M USD.

When did HCW Biologics complete a stock split?▼

HCW Biologics has not had any recent stock splits.